This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheng, J. Articles by Repasky, E. A. Search for Related Content PubMed PubMed Citation Articles by Cheng, J. Articles by Repasky, E. A.

Research Articles: Therapeutics

Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL

Departments of ¹ Immunology, ² Cancer Pathology and Prevention, ³ Medicine, and ⁴ Cellular Stress Biology, Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Elizabeth Repasky, Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-3133; Fax: 716-845-8552; E-mail: elizabeth.repasky{at}roswellpark.org

Targeting death receptors with tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) has the remarkable potential to selectively kill malignant cells whereas normal cells are largely unaffected by this treatment. However, some tumor cells, including leukemia cells, exhibit resistance to this molecule. To investigate the basis for resistance of leukemia cells to the zinc-bound form of Apo2 ligand (Apo2L)/TRAIL, which is currently being evaluated in clinical trial, we isolated several resistant HL60 clones from parental HL60 cells by selection using the recombinant Apo2L/TRAIL. Differing resistance mechanisms were identified and characterized in these Apo2L/TRAIL-resistant clones. In one case, the level of the cell-surface death receptor DR4, but not DR5, was significantly decreased. However, these cells did undergo apoptosis in response to another form of recombinant TRAIL, histidine-tagged TRAIL, suggesting differing contributions of DR4 and DR5 in the response to these two forms of TRAIL. In the case of other clones, expression of procaspase-8 protein was lost and this was associated with a novel Leu²²Phe²² point mutation in CASP-8 gene. These results show that cells within a given tumor can have widely distinct mechanisms underlying resistance to Apo2L/TRAIL. [Mol Cancer Ther 2006;5(7):1844–53]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 1/26/06; revised 5/ 5/06; accepted 5/16/06.

This article has been cited by other articles:

				J. Han, W. Hou, L. A. Goldstein, C. Lu, D. B. Stolz, X.-M. Yin, and H. Rabinowich Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor Cells J. Biol. Chem., July 11, 2008; 283(28): 19665 - 19677. [Abstract] [Full Text] [PDF]

				R. M. Locklin, E. Federici, B. Espina, P. A. Hulley, R. G. G. Russell, and C. M. Edwards Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis Mol. Cancer Ther., December 1, 2007; 6(12): 3219 - 3228. [Abstract] [Full Text] [PDF]

				T. F. Gajewski On the TRAIL Toward Death Receptor-Based Cancer Therapeutics J. Clin. Oncol., April 10, 2007; 25(11): 1305 - 1307. [Full Text] [PDF]